HERTHENA-BREAST-01: A PHASE 1B/2, MULTICENTER, OPEN-LABEL, DOSE FINDING
STUDY TO EVALUATE THE SAFETY AND ANTITUMOR ACTIVITY OF PATRITUMAB
DERUXTECAN IN PARTICIPANTS WITH HER2 POSITIVE UNRESECTABLE LOCALLY
ADVANCED BREAST CANCER OR METASTATIC BREAST CANCER
- Registry ID
- MK-1022-009
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- MERCK CANADA INC
- Start date
- 2025-09-18
- Last update
- 2025-07-07
Conditions
- BREAST CANCER METASTATIC
- BREAST CANCER
Related clinical trials
- 68Ga FAPI PET/CT Evaluation of Axillary Lymph Node Status After Neoadjuvant Therapy in Patients With Clinical Axillary Lymph Node Positive Breast Cancer
- Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients
- A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB PLUS RIBOCICLIB PLUS FULVESTRANT VERSUS PLACEBO PLUS RIBOCICLIB PLUS FULVESTRANT IN PATIENTS WITH ENDOCRINE-RESISTANT HORMONE-RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WITH CHROMOSOME 8P LOSS AND WITHOUT A PIK3CA MUTATION
- A PHASE IB/II MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY
EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF
GDC-4198 ALONE AND IN COMBINATION WITH GIREDESTRANT IN
COMPARISON WITH ABEMACICLIB AND GIREDESTRANT IN
PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC
ESTROGEN RECEPTOR-POSITIVE, HER2 NEGATIVE BREAST CANCER
WHO HAVE PREVIOUSLY PROGRESSED DURING OR AFTER A CDK4/6
INHIBITOR
- A PHASE 3 OPEN-LABEL RANDOMIZED STUDY ASSESSING THE EFFICACY AND
SAFETY OF RLY-2608 + FULVESTRANT VERSUS CAPIVASERTIB + FULVESTRANT AS TREATMENT FOR
PIK3CA-MUTANT HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR
2 NEGATIVE (HR+/HER2-) LOCALLY ADVANCED OR METASTATIC BREAST CANCER FOLLOWING RECURRENCE OR PROGRESSION ON OR AFTER TREATMENT WITH A CDK4/6 INHIBITOR
- A PHASE I/II, MULTI-SITE, OPEN-LABEL, TWO-PART TRIAL TO EVALUATE THE EFFICACY, SAFETY,
AND PHARMACOKINETICS OF BNT323 IN COMBINATION WITH BNT327 IN PARTICIPANTS
WITH ADVANCED BREAST CANCER
View on source registry